AI assistant
CAMBIUM BIO LIMITED — Capital/Financing Update 2021
Nov 4, 2021
64666_rns_2021-11-04_a3878f14-c7b7-40dc-af84-b7acde891c77.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [160 x 33] intentionally omitted <==
Friday, 5 November 2021
The Manager Market Announcement Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000
REGENEUS LTD (ASX:RGS) NEW LIFE SCIENCES PLACEMENT AGREEMENT - EXTENSION OF SECOND CLOSING DATE
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, today announced that it has agreed to extend by 60 days the date by which the second placement of the Company’s shares to New Life Sciences Capital, LLC ( New Life Sciences ) is to occur.
Regeneus announced on 7 May 2021 that it secured up to $4.5 million in a three-stage placement of the Company’s ordinary shares ( Shares ) to New Life Sciences, a U.S.-based institutional investor, comprising:
-
an initial placement of $1,590,000 of Shares to raise $1,500,000 which occurred on 12 May 2021;
-
a second placement of $1,590,000 of Shares to raise $1,500,000 which was to occur by 8 November 2021 and, as a result of the extension, will now occur by 7 January 2022; and
-
a third placement of $1,500,000 of Shares to raise $1,500,000 will occur, subject to the mutual consent of the Investor and the Company, within 12 months.
Further details regarding the terms of the placement to New Life Sciences are set out in the Company’s ASX announcement dated 7 May 2021.
The extension of the date by which the second placement is to occur accords with Regeneus’s current funding requirements.
-ENDS-
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.
Authorisation & Additional information
Investor and Media Contact
This announcement was authorised by the WE Communications Chairman and Company Secretary of Regeneus T: 03 8866 1200 Ltd E: [email protected]
2 Paddington Street, Paddington, NSW 2021 Ph: 1300 995 098 • www.regeneus.com.au • ABN 13 127 035 358